SCHEMBL5830637

SCHEMBL5830637

Cc1cc(Cl)cc(Cl)c1S(=O)(=O)Nc1nnc(CCN2CCOCC2)s1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
HSD11B1 P28845 1/20 0.44
KMT2A Q03164 3/20 0.43
GLS O94925 2/20 0.40
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
CA1 P00915 1/20 0.38
NMT1 P30419 1/20 0.38
MEN1 O00255 1/20 0.38
CYP2D6 P10635 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
USP2 O75604 1/20 0.37
HTR6 P50406 1/20 0.37
ENPP2 Q13822 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5830942 0.93 HSD11B1 (0.49) ALDH1A1MAPK1HSD17B10HSD11B1KMT2A
SCHEMBL6930851 0.90 AKT1 (0.44) ALDH1A1KMT2APOLBCA1MEN1
SCHEMBL5830665 0.86 HSD11B1 (0.39) ALDH1A1HSD11B1KMT2AGLSPOLB
SCHEMBL5831200 0.83 HSD11B1 (0.60) ALDH1A1HSD11B1KMT2AKDM4EPOLB
SCHEMBL5831671 0.83 HSD11B1 (0.46) ALDH1A1MAPK1HSD11B1KMT2ANMT1
SCHEMBL5831079 0.82 KMT2A (0.51) ALDH1A1MAPK1HSD17B10HSD11B1KMT2A
Hydrochloric Acid SCHEMBL3611528 0.81 HSD11B1 (0.60) ALDH1A1MAPK1HSD11B1KMT2AKDM4E
SCHEMBL6614389 0.80 HSD11B1 (0.42) ALDH1A1MAPK1HSD11B1KDM4ENMT1
SCHEMBL5831699 0.79 HSD11B1 (0.44) ALDH1A1MAPK1HSD17B10HSD11B1KMT2A
SCHEMBL5831264 0.79 ALDH1A1 (0.50) ALDH1A1MAPK1HSD17B10HSD11B1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 ALDH1A1 63/4885MAPK1 608/4885HSD17B10 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.